| http://www.w3.org/ns/prov#value | - Prophylaxis with appropriate antihistamines before initiating therapy with SUSTIVA in pediatric patients should be considered. 5.8 Hepatotoxicity Monitoring of liver enzymes before and during treatment is recommended for patients with underlying hepatic disease, including hepatitis B or C infection; patients with marked transaminase elevations; and patients treated with other medications associate
|
